Cotellic (cobimetinib) vs Braftovi (encorafenib)

Cotellic (cobimetinib) and Braftovi (encorafenib) are both targeted therapies used in the treatment of melanoma with a specific mutation known as BRAF V600E or V600K. Cotellic is a MEK inhibitor that is often used in combination with another medication called vemurafenib, a BRAF inhibitor, to block cancer cell growth. In contrast, Braftovi is a BRAF inhibitor that can be used alone or in combination with a MEK inhibitor such as binimetinib, offering a different treatment approach that might be preferable depending on the specific clinical profile and history of the patient. When deciding which medicine is right for an individual, it is crucial to consult with a healthcare provider to consider the specific mutation present, the side effect profile of each medication, and the patient's overall health status.

Difference between Cotellic and Braftovi

Metric	Cotellic (cobimetinib)	Braftovi (encorafenib)
Generic name	cobimetinib	encorafenib
Indications	Used in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation	Used alone or in combination with binimetinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
Mechanism of action	MEK inhibitor (mitogen-activated protein kinase/extracellular signal-regulated kinase)	BRAF inhibitor
Brand names	Cotellic	Braftovi
Administrative route	Oral	Oral
Side effects	Diarrhea, rash, abdominal pain, fatigue, nausea, fever, liver abnormalities, photosensitivity	Fatigue, nausea, vomiting, abdominal pain, joint pain, rash, retinal pigment epithelial detachment
Contraindications	Hypersensitivity to cobimetinib or any of its excipients	Hypersensitivity to encorafenib or any of its excipients
Drug class	Antineoplastic agent, MEK inhibitor	Antineoplastic agent, BRAF inhibitor
Manufacturer	Genentech, Inc.	Pfizer Inc.

Efficacy

Efficacy of Cotellic (Cobimetinib) in Skin Cancer

Cotellic (cobimetinib) is a medication that has been approved for use in combination with another drug called Zelboraf (vemurafenib) for the treatment of a specific type of skin cancer known as melanoma. It is specifically indicated for patients with melanoma that cannot be removed by surgery or that has metastasized, and whose tumors express a gene mutation called BRAF V600E or V600K, as detected by an FDA-approved test. Cobimetinib works by inhibiting a protein called MEK, which is part of a larger signaling pathway that contributes to cell growth and survival, and its mutation is implicated in the development of cancer.

Efficacy of Braftovi (Encorafenib) in Skin Cancer

Braftovi (encorafenib), like Cotellic, is also targeted at BRAF-mutant melanoma. It is a BRAF inhibitor that is used in combination with another medication called Mektovi (binimetinib), a MEK inhibitor, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. The combination of Braftovi and Mektovi has been shown to be effective in delaying the progression of melanoma and improving survival rates in patients with this mutation. Encorafenib targets and inhibits the activity of the mutated BRAF protein, thereby slowing down or stopping the growth of the cancer cells.

Combination Therapy and Its Impact on Skin Cancer

The combination of Cotellic and Zelboraf, as well as the combination of Braftovi and Mektovi, represent advances in the treatment of BRAF-mutant melanoma. Clinical trials have demonstrated that these combination therapies can significantly improve outcomes for patients with advanced melanoma. For instance, the combination of cobimetinib and vemurafenib has been shown to improve progression-free survival compared to vemurafenib alone. Similarly, the combination of encorafenib and binimetinib has been found to improve overall survival and progression-free survival compared to some other standard therapies.

Conclusion

In conclusion, both Cotellic (cobimetinib) and Braftovi (encorafenib) have demonstrated efficacy in the treatment of BRAF V600 mutation-positive melanoma, particularly when used in combination with other targeted therapies. These combinations have become an important part of the treatment regimen for patients with advanced melanoma, offering improved outcomes in terms of progression-free survival and overall survival. It is important for patients to undergo appropriate testing to determine the presence of the BRAF V600 mutation in their tumors to ensure the suitability of these treatments.

Regulatory Agency Approvals

Cotellic

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Braftovi

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Cotellic or Braftovi today

If Cotellic or Braftovi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Cotellic

Buy Braftovi

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: